Treatment of hepatocellular carcinoma with sub-selective transcatheter arterial oily chemoinfusion

Techniques in Vascular and Interventional Radiology

Volumn 5, Issue 3, 2002, Pages 127-131

  Kim, Pamina ^a   Prapong, Wijan ^a   Sze, Daniel Y ^a   So, Samuel K ^a   Razavi, Mahmood K ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CISPLATIN; DOXORUBICIN; ETHIODIZED OIL; GELFOAM;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; PROGNOSIS; PROTEIN BLOOD LEVEL; SUBSELECTIVE TRANSCATHETER ARTERIAL OILY CHEMOINFUSION; TREATMENT OUTCOME;

EID: 0036765633     PISSN: 10892516     EISSN: None     Source Type: Journal    
DOI: 10.1053/tvir.2002.36424     Document Type: Article

References (13)

1. London WT: Primary hepatocellular carcinoma - Aetiology, pathogenesis, and prevention. Hum Pathol 1981;12:1085-1097
2. Okuda D, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56:918-928, 1985
3. Farmer DG, Rosove MH, Shaked A, et al: Current treatment modalities for hepatocellular carcinoma. Ann Surg 219:236-247, 1994
4. Okuda K, Liver Cancer Study Group of Japan: Primary liver cancers in Japan. Cancer 45:2663-2669, 1980
5. Stuart KE, Anand AJ, Jenkins RL: Hepatocellular carcinoma in the United States: Prognostic features, treatment, outcome, and survival. Cancer 11:2217-2222, 1996
6. Lehnert T, Herfarth C: Chemoembolization for hepatocellular carcinoma. What, when, and for whom? Ann Surg 224:1-3, 1996
7. Chung JW, Park HJ, Han JK, et al: Hepatic tumors: Predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33-40, 1996
8. Sigurdson E, Ridge J, Daly J. Intra-arterial infusion of doxorubicin with degradable starch microspheres. Improvement of hepatic tumor drug uptake. Arch Surg 121:1277-1281, 1986
9. Group d'Etude et de treatment du carcinoma hepatocellulaaire: A comparison of lipiodol chemoembolisation and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med. 332:1256-1261, 1995
10. Chan AO, Yuen MF, Hui CK, et al: A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94:1747-1752, 2002
11. Stefanini GF, Amorati P, Biselli M, et al: Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. Cancer 75:2427-2434, 1995
12. Kamada K, Nakanishi T, Kitamoto M, et al: Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable HCC: Comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 127:847-854, 2001
13. Chen MS, Li JQ, Zhang YQ, et al: High dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 8:74-78, 2002